DigiPharm Partners With Leading Telecommunications Company SwissCom

Digipharm, a blockchain venture looking to utilize innovating technology to be the pioneer of sustainable and value-based healthcare delivery, has announced their official cooperation with Swisscom Blockchain, founded by Swisscom. Digipharm wants to overcome barriers to patient access, reduce costs for stakeholders, as well as make personalized healthcare a reality.

Healthcare Is Growing More Important

With annual global drug prescription spending to increase to $1.5 trillion by 2021, and 75% of healthcare payments to be value-based by 2020, healthcare is only becoming more prevalent. Especially with strides in medicine and technology making people live longer, healthcare is only going to become more important as people continue to live healthier lives.

Ahmed Abdulla, Founder and CEO of Digipharm Commented:

“Our alliance with Swisscom Blockchain as our technical development partners is somewhat unprecedented in the industry and a big step towards the application of Digipharms’ solutions in real world settings. With this agreement we are able to accelerate the development of robust, scalable platforms with the highest levels of credibility, data privacy and inherent security. We are working extremely hard, hand in hand with the world class team at Swisscom Blockchain to bring fair pricing to healthcare and push the transition towards personalised therapy. This is massive news for the Digipharm team, our industry partners, investors and most importantly, healthcare systems and patients.”

One of Top Companies In Switzerland

Swisscom is a giant in Switzerland, being the leading telecommunications company, and one of the top IT companies as well. With over $12.2 in revenue in 2017, over 66% of the population use the Swisscom network, and 51`% of the company is owned by the Swiss Confederation.

Swisscom announced their exploration into blockchain technology September 2017, and since then has been approached by hundreds of blockchain projects. Swisscom has been highly selective in whom they choose to associate themselves with, which is another testament for Digipharm.

Digipharm’s Collaboration With Swisscom

Digipharm will be collaborating with Swisscom Blockchain in the areas of development, infrastructure, as well as overall strategy. Their Minimal Viable Product (MVP) is currently in development, and will be ready for deployment following their Initial Coin Offering.

Sven Möller, Swisscom Blockchain Head of ICO Advisory:

“Swisscom Blockchain is proud to be in cooperation with Digipharm in the development of their game-changing platforms. We believe their platforms and vision are well placed to lead the advance of real world uptake for blockchain technology in healthcare. We are convinced that our work together can make an impact on the global scale and we are delighted to support innovation at a local level. Our team of experts will work side by side with the Digipharm team to bring their vision to life, bring fair pricing to healthcare and benefit patients all over the world.”

As you can see, both parties are equally enthusiastic regarding the partnership. Digipharm gets to take advantage of the resources and world class talent afforded to them from Swisscom Blockchain, and the leading telecommunications company gets to support innovating that they believe in.

To learn more visit the Website: https://digipharm.ch/

Meet the team on LinkedIn: https://www.linkedin.com/company/digipharm/

Chat with us on Telegram: https://t.me/joinchat/ExOHxk-TuOplQDbBWXaLaQ

Connect on Facebook: https://www.facebook.com/digipharmteam/

Disclaimer. This article is paid and provided by a third-party source and should not be viewed as an endorsement by CoinIdol. Readers should do their own research before investing funds in any company. CoinIdol shall not be responsible or liable, directly or indirectly, for any damage or loss caused or alleged to be caused by or in connection with the use of or reliance on any such content, goods or services mentioned in this article.